Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Hep C Drug Shows Unprecedented Effectiveness

By Drug Discovery Trends Editor | September 6, 2011

Drug developer Pharmasset Inc. hit a “home run” with results from a mid-stage study of a potential hepatitis C virus treatment, according to a Citi analyst.

Pharmasset, based in Princeton, N.J., said results from a study of the drug candidate labeled PSI-7977 showed that 91 percent of the subjects enrolled, or 43 out of 47 patients, had undetectable levels of the virus 12 weeks after their treatment stopped. The company is studying a 400-milligram dose of PSI-7977 used in combination with two other treatments in patients with a form of the hepatitis C virus who had not been treated previously.

Pharmasset will monitor the patients for a total of 24 weeks, or six months, after treatment stops. Results from the study will be presented in November at a meeting of the American Association for the Study of Liver Diseases.

Pharmasset has no products on the market. The company said in July its fiscal third-quarter loss widened to $22.6 million, or 60 cents per share, due to continued development of the drug. It reported $246,000 in revenue, which comes from partnership payments from Swiss drugmaker Roche Holding AG.

Analyst Yaron Werber, MD said in a research note the study’s cure rate was the highest ever seen, and it surpassed his expectation of between 85% and more than 90%.

“This should cement confidence in the long-term outlook, in our view,” Werber wrote.

In August, Werber said PSI-7977 will become part of the backbone for hepatitis treatments, due in part to its high potency.

Date: September 6, 2011
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50